These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24000418)

  • 1. Should you take an erectile dysfunction drug to also ease urinary woes? We think not. Standard medications to treat the symptoms of an enlarged prostate are still the best first choice for men.
    Harv Mens Health Watch; 2013 Jun; 17(11):1, 7. PubMed ID: 24000418
    [No Abstract]   [Full Text] [Related]  

  • 2. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Porst H; McVary KT; Montorsi F; Sutherland P; Elion-Mboussa A; Wolka AM; Viktrup L
    Eur Urol; 2009 Oct; 56(4):727-35. PubMed ID: 19409693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
    Yuan RQ
    Zhonghua Nan Ke Xue; 2012 Dec; 18(12):1147-51. PubMed ID: 23405801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or α-adrenoceptor antagonist?
    Wyllie MG
    BJU Int; 2012 Apr; 109(7):965-6. PubMed ID: 22373009
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Zhao C; Kim SH; Lee SW; Jeon JH; Kang KK; Choi SB; Park JK
    BJU Int; 2011 Jun; 107(12):1943-7. PubMed ID: 21054754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tadalafil for benign prostatic hyperplasia.
    Drug Ther Bull; 2013 Aug; 51(8):93-6. PubMed ID: 23949822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment on: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Volpe A
    Eur Urol; 2009 Oct; 56(4):735-6. PubMed ID: 19409694
    [No Abstract]   [Full Text] [Related]  

  • 12. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
    Goldfischer E; Kowalczyk JJ; Clark WR; Brady E; Shane MA; Dgetluck N; Klise SR
    Urology; 2012 Apr; 79(4):875-82. PubMed ID: 22341603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men.
    Mazur DJ; Helfand BT; McVary KT
    Urol Clin North Am; 2012 Feb; 39(1):77-88. PubMed ID: 22118347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
    Hwang TI; Chu SH; Lin MS; Chen CS; Lee LM; Chang HC; Yeh SD; Chen WH; Chiang PH
    Kaohsiung J Med Sci; 2012 Aug; 28(8):429-34. PubMed ID: 22892164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile dysfunction drug approved to treat BPH symptoms.
    Mayo Clin Health Lett; 2012 Apr; 30(4):4. PubMed ID: 22649816
    [No Abstract]   [Full Text] [Related]  

  • 18. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.
    Donatucci CF; Brock GB; Goldfischer ER; Pommerville PJ; Elion-Mboussa A; Kissel JD; Viktrup L
    BJU Int; 2011 Apr; 107(7):1110-6. PubMed ID: 21244606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
    Rosen R; Seftel A; Roehrborn CG
    Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.